文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气心脑血管急症

体外膜氧合后五年:健康相关生活质量与患者结局的前瞻性队列研究

Five Years After Extracorporeal Membrane Oxygenation: A Prospective Cohort Study of Health-Related Quality of Life and Patient Outcomes.
PubMed 文献 · Crit Care Med · 2025-10-15
一句话结论体外膜氧合(ECMO)后5年生存率36%,幸存者健康相关生活质量满意(中位EuroQol指数0.82),但约六成存在疼痛或不适。

该前瞻性多中心观察性队列随访研究纳入荷兰10个ECMO中心2017年8月至2019年7月期间接受ECMO支持的患者428例,评估5年生存率、健康相关生活质量和职业状态。结果示院内生存230例(54%),1年生存213例(50%),5年生存155例(36%);呼吸支持、心脏支持和体外心肺复苏的5年生存率分别为42%、39%和25%。问卷应答率72%,5年幸存者健康相关生活质量满意,中位EuroQol指数0.82(四分位距0.73-0.98),但39%存在活动能力轻度至中度受损,44%日常活动受损,60%有疼痛或不适;41%就业,31%退休,26%永久丧失工作能力。作者认为ECMO支持患者长期结局良好。

要点

  • ECMO后5年生存率36%(155/428),其中呼吸支持42%、心脏支持39%、体外心肺复苏25%。
  • 5年幸存者健康相关生活质量满意,中位EuroQol指数0.82(四分位距0.73-0.98)。
  • 5年幸存者中60%报告疼痛或不适,44%日常活动受损,39%活动能力轻度至中度受损。
  • 5年幸存者职业状态:41%就业,31%退休,26%永久丧失工作能力。
  • 作者结论认为ECMO支持患者长期结局良好,尽管日常功能存在一定损害。

适用人群与场景

  • 荷兰10个ECMO中心(覆盖荷兰90%以上ECMO支持患者)2017年8月至2019年7月期间接受ECMO支持的呼吸或心脏衰竭患者。

研究设计与关键结果

  • 研究类型:前瞻性多中心观察性队列随访研究;样本量428例;10个ECMO中心;人群为接受ECMO支持的呼吸或心脏衰竭患者;无干预。
  • 主要结局:院内生存230例(54%),1年生存213例(50%),5年生存155例(36%)。
  • 5年生存率:呼吸支持42%,心脏支持39%,体外心肺复苏25%。
  • 健康相关生活质量:问卷应答率72%;5年幸存者中位EuroQol指数0.82(四分位距0.73-0.98);39%报告活动能力轻度至中度受损,44%日常活动受损,60%疼痛或不适。
  • 职业状态:5年幸存者中41%就业,31%退休,26%永久丧失工作能力。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性队列随访研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为ECMO支持患者长期结局良好,5年幸存者健康相关生活质量满意,尽管日常功能存在一定损害。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To report on 5-year survival, health-related quality of life (HRQoL), and occupational status of patients with respiratory or cardiac failure, who were supported with extracorporeal membrane oxygenation (ECMO).

DESIGN: A prospective multicenter observational cohort follow-up study.

SETTING: ICUs of ten ECMO centers in the Netherlands, representing more than 90% of all patients supported with ECMO in the Netherlands.

PATIENTS: Patients supported with ECMO between August 2017 and July 2019.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Survival was assessed by consulting the Dutch municipal records database. All 5-year survivors received a questionnaire. HRQoL was assessed using the standardized EuroQol 5D Five Levels instrument, and occupational status was assessed using the standardized Institute for Medical Technology Assessment Productivity Cost Questionnaire. Of the initial 428 participants, 230 (54%) survived the hospital admission, 213 (50%) survived the first year, and 155 (36%) survived 5 years. Five-year survival rates were 42% for patients receiving ECMO for respiratory support, 39% for cardiac support, and 25% for extracorporeal cardiopulmonary resuscitation. The response rate to the questionnaire was 72%. HRQoL was rated satisfactory at 5 years, with a median EuroQol index of 0.82 (interquartile range, 0.73-0.98). Five-year survivors reported slight-to-moderate impairment of mobility (39%), impairment of usual activities (44%), and pain or discomfort (60%). After 5 years, the majority of patients were either employed (41%), retired (31%), or permanently declared unfit for work (26%).

CONCLUSIONS: Long-term outcome in patients supported with ECMO is good. Five-year survivors reported that HRQoL was satisfactory despite some impairment in day-to-day functioning.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Jolink FEJ, Onrust M, Dos Reis Miranda D, et al. Five Years After Extracorporeal Membrane Oxygenation: A Prospective Cohort Study of Health-Related Quality of Life and Patient Outcomes. Crit Care Med. 2025. PMID: 41091003. doi:10.1097/CCM.0000000000006900

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。